Summit Therapeutics shares are trading higher after a Form4 filing showed COO Manmeet Soni bought roughly 17 million shares at an average price of $0.29.
Portfolio Pulse from Benzinga Newsdesk
Summit Therapeutics' COO Manmeet Soni has purchased approximately 17 million shares at an average price of $0.29, according to a Form4 filing. This has led to an increase in the company's stock price.
October 17, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Summit Therapeutics' stock price has increased following the purchase of 17 million shares by COO Manmeet Soni.
Insider trading, especially by high-ranking executives, often signals confidence in the company's future prospects. This can influence other investors to buy the stock, leading to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100